Calcium channel blockers and the risk of cancer: A preclinical assessment

Cardiovascular Drugs and Therapy

Volumn 12, Issue 2, 1998, Pages 157-169

  Ahr, Hans J ^a   Bomhard, Ernst ^a   Enzmann, Harald ^a   Karbe, Eberhard ^a   Mager, Harry ^a   Sander, Erich ^a   Schlüter, Gerhard ^a  

^a BAYER AG   (Germany)

Author keywords

Apoptosis; Calcium channel blockers; Carcinogenesis; Cell proliferation; Dihydropyridines; Tumor promotion

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER; CARCINOGENICITY; CAUSE OF DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TUMOR PROMOTION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CARCINOGENS; DIET; FEMALE; MALE; MICE; NEOPLASMS, EXPERIMENTAL; RATS; RATS, WISTAR; RISK ASSESSMENT; TIME FACTORS;

EID: 0031746304     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007727010076     Document Type: Article

References (105)

1. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium-channel blockers increase the risk of cancer. Am J Hypertens 1996;9:695-699.
2. Williams GM, Iatropoulos J, Weisburger JH. Chemical carcinogen mechanisms of action and implication for testing methodology. Exp Toxic Pathol 1996;48:101-111.
3. Physicians' Desk Reference. Montvale, NJ: Medical Economics Data Production Company, 1995.
4. Peto R, Pike MC, Dayne et al. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal. IARC Monographs, Suppl. 2, Lyon, France: IARC, 1980:311-426.
5. Ryan LM. Efficiency of age-adjusted tests in animal carcinogenicity experiments. Biometrics 1985;41:525-531.
6. Report of the NTP Ad Hoc Panel on Chemical Carcinogenesis Testing and Evaluation. U.S. Department of Health and Human Services, Research Triangle 1984:212.
7. Lee P. Assumption in analyses of the bioassay: A statisticians view. In: Grice HC, Ciminera JL, eds. Carcinogenicity - The Design, Analysis, and Interpretation of Long-Term Animal Studies. New York: Springer, 1988:7.
8. Gart J, Krewski D, Lee P, Tarone R, Wahrendorf J. Statistical Methods in Cancer Research, Vol. III: The Design and Analysis of Long-Term Animal Experiments. Lyon, France: IARC, 1987.
9. Nyska A, Waner T, Galliano A, Fick A. Constipation and megacolon in rats related to treatment with Oxodipine, a calcium antagonist. Toxicol Pathol 1994;22:589-594.
10. Bomhard E, Karbe E, Löser E. Spontaneous tumors of 2000 Wistar TNO/W70 rats in 2-year carcinogenicity studies. J Environ Pathol 1986;7:35-52.
11. Bomhard E, Rinke M. Frequency of spontaneous tumors in Wistar rats in 2-year studies. Exp Toxicol Pathol 1994;46: 17-29.
12. Bomhard E. Frequency of spontaneous tumors in NMRI mice in 21-month studies. Exp Toxicol Pathol 1993;45: 269-289.
13. Alison RH, Capen CC, Prentice DE. Neoplastic lesions of questionable significance to humans. Toxicol Pathol 1994;22: 179-186.
14. Purchase J. Current knowledge of mechanisms of carcinogenicity: Genotoxins vs. non-genotoxins. In: McAuslane JAN, Limley CE, Walker SR, eds. The Carcinogenicity Debate. Quay Publishing, Lancaster, UK 1992:3-24.
15. Grasso P, Hinton RH. Evidence for and possible mechanisms of non-genotoxic carcinogenesis in rodent liver. Mutat Res 1991;248:271-290.
16. Hoel DG, Haseman JK, Hogan MD, Huff J, McConnell EE. The impact of toxicity studies: Implications for risk assessment. Carcinogenesis 1988;9:2045-2052.
17. Monro A. Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? Exp Toxicol Pathol 1996; 48:155-166.
18. Ames BN, Gold LS. Too many rodent carcinogens. Science 1990;249:970-971.
19. Thorgeirsson UP, Dalgard DW, Reeves J, Adamson RH. Tumor incidence in a chemical carcinogenesis study of non-human primates. Regul Toxicol Pharmacol 1994;19:130-151.
20. Berridge MJ. The biology and medicine of calcium signalling. Mol Cell Endocrinol 1994;98:119-124.
21. Berridge MJ. Calcium signalling and cell proliferation. Bio Essays 1995;17:491-500.
22. Takuwa N, Zhou W, Takuwa Y. Calcium, calmodulin and cell cycle progression. Cell Signalling 1995;7:93-104.
23. Lu KP, Means AR. Regulation of the cell cycle by calcium and calmodulin. Endocr Res 1993;14:40-58.
24. Whitfield J F. Calcium signals and cancer. Crit Rev Oncogen 1992;3:55-90.
25. Veigl ML, Vanaman TC, Sedwick WD. Calcium and calmodulin in cell growth and transformation. Biochem Biophys Acta 1984;738:21-48.
26. Dragan YP, Hully J, Crow R, Mass M, Pitot HC. Incorporation of bromodeoxyuridine in glutathione S-transferase-positive hepatocytes during rat multistage hepatocarcinogenesis. Carcinogenesis 1994;15:1939-1947.
27. Huang SN, Chisari FV. Strong sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 1995;21:620-626.
28. Robinson BG. Molecular genetics of thyroid and parathyroid neoplasia. Austr N Z J Surg 1995;65:77-79.
29. DiGiovanni J, Rho O, Xian W, Beltran L. Role of the epidermal growth factor receptor and transforming growth factor alpha in mouse skin carcinogenesis. Prog Clin Biol Res 1994;387:113-138.
30. De Koster E, Buset M, Fernandes E, Deltenre M. Helicobacter pylori: The link with gastric cancer. Eur J Cancer Prev 1994;3:247-257.
31. Hulka BS, Liu ET, Lininger RA. Steroid hormones and risk of breast cancer. Cancer 1994;74:1111-1124.
32. Coffey RJ Jr., Meise KS, Matsui Y, Hogan BL, Dempsey PJ, Halter SA. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7, 12-dimethylbenzanthracene. Cancer Res 1994;54:1678-1683.
33. Rosin MP, Saad el Din Zaki S, Ward AJ, Anwar WA. Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. Mutat Res 1994;305:283-292.
34. Parkin DM, Ohshima H, Srivatanakul P, Vatanasapt V. Cholangiocarcinoma: Epidemiology mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev 1993;2:537-544.
35. Short BG. Cell proliferation and renal carcinogenesis. Environ Health Perspert 1993;101:115-120.
36. Croy RG. Role of chemically induced cell proliferation in carcinogenesis and its use in health risk assessment. Environ Health Perspect 1993;101:289-302.
37. Tomatis L. Cell proliferation and carcinogenesis: A brief history and current view based on an IARC workshop report. Environ Health Perspect 1993;101:149-151.
38. Fleckenstein A. Fundamental actions of calcium antagonists on myocardial cardiac pacemaker cell membranes. In Weiss GB, ed. New Perspectives on Calcium Antagonists. Clinical Physiology Series, American Physiological Society, 1981: 59-81.
39. Kass GEN, Llopis J, Chow SC, Duddy SK, Orrenius S. Receptor-operated calcium influx in rat hepatocytes. J Biol Chem 1990;265:17486-17492.
40. Sperti G, Colucci WS. Calcium influx modulates DNA synthesis and proliferation in A7R5 vascular smooth muscle cells. Eur J Pharmacol 1991;206:279-284.
41. Handley DA, van Valen RG, Melden MK, Saunders RN. Supression of rat carotid lesion development by the calcium channel blocker PN 200-110. Am J Pathol 1986;124:88-93.
42. Hecker M, Winter I, Schray UB, Busse R. Inhibition of DNA synthesis in cultivated human endothelial cells by Ca-antagonists. Z Kardiol 1993;82:113.
43. 2+ channels. Kidney Int 1996;49:868-879.
44. Gelfand EW, Cheung RK, Grinstein S, Mills GB. Characterization of the role for calcium influx in mitogen-induced triggering of human T cells. Identification of calcium-dependent and calcium-independent signals. Eur J Immunol 1986;16:907-912.
45. Dugas B, Vazquer A, Klein B, Delfraissy JF, Rammou M, Gerard JP, Galanaud P. Early events in human B cell activation: Metabolic pathways vary according to the first signal used. Eur J Immunol 1986;16:1609-1614.
46. Brent LH, Butler JL, Woods WT Jr., Bubien JK. Transmembrane ion conductance in human B lymphocyte activation. J Immunol 1990;145:2381-2389.
47. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 1992; 52:2413-2418.
48. Worley JF, Strobl JS. Voltage-dependent calcium channels in MCF-T human breast cancer cells and inhibition of cell growth by calcium channel antagonists. Cancer Chemother Pharmacol 1989;24:84.
49. Sugimoto K, Simard J, Haagensen DE, Labrie F. Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. Steroid Biochem. Mol Biol 1994;51: 167-174.
50. Bertrand V, Bastie MJ, Vaysse X, Pradayrol L. Inhibition of gastrin induced proliferation of AR 4-2S cells by calcium channel antagonists. Int J Cancer 1994;56:427-432.
51. Codignola A, Tarroni P, Clementi F, Pollo A, Lovallo M, Carbone E, Sher E. Calcium channel subtypes controlling serotonin release from human small cell lung carcinoma cell lines. J Biol Chem 1993;268:26240-26247.
52. Schüller HM, Miller MS, Reznik GK. Antiproliferative effects of dihydropyridines on human lung cancer cell lines. Proc Am Assoc Cancer Res 1993;34:347.
53. Piontek M, Hengels KJ. Effect of calcium-modifying agents on the growth of human gastric carcinoma cells in vitro. Anticancer Res 1992;12:1559-1563.
54. 2+/calmodulin-dependent pathway of human thyroid carcinoma cell line, NIM 1. Jpn J Cancer Res 1995;86:670-677.
55. Kunert-Radek J, Stepien H, Stawowy A, Pawlikowski M. Involvement of calcium channels in control of the pituitary tumoral cell proliferation in vitro. Neuroendocrinol Lett 1989;11:339-345.
56. Lee YS, Sayeed MM, Wurster RD. Inhibition of cell growth and intracellular CA2 mobilization in human brain tumor cells by CA2 channel antagonists. Mol Chem Neuropathol 1994;22:81-95.
57. Schmidt WF, Huber KR, Ettinger RS, Neuberg RW. Antiproliferative effect of verapamil alone on brain tumor cells in vitro. Cancer Res 1988;48:3617-3621.
58. Jensen RL, Origitano TC, Lee YS, Weber M, Wurster RD. In vitro growth inhibition of growth factor stimulated meningioma cells by calcium channel antagonists. Neurosurgery 1995;36:365-374.
59. Bruserud O, Nesthus I, Pawelec G. In vitro effect of R-verapamil on acute myelogenous leukemia blast cells. Studies of cytokine secretion and cytokine-dependent blast proliferation. Cancer Chemother Pharmacol 1995;37:70-78.
60. Shirakawa F, Yamashita U, Oda S, Chiba S, Eto S. Calcium dependency in the growth of adult T-cell leukemia cells in vitro. Cancer Res 1986;46:658-661.
61. Okazaki T, Mochizuki T, Tashima M, Sawada H, Uchino H. Role of intracellular calcium ion in human promyelocytic leukemia HL-60 cell differentiation. Cancer Res 1986;46: 6059-6063.
62. Sato K, Ishizuka J, Cooper CW, et al. Inhibitory effect of calcium channel blockers on growth of pancreatic cancer cells. Pancreas 1994;9:193-202.
63. Hirai A, Ishizuka J, Cooper CW, Townsend CM, Thompson JC. Effect of calcium channel blockers on growth of colon cancer cells. Gastroenterology 1994;106:A392.
64. Corcoran GB, Fix L, Jones DP, et al. Apoptosis: Molecular control point in toxicity. Toxicol Appl Pharmacol 1994;128: 169-181.
65. Orrenius S. Apoptosis: Molecular mechanisms and implications for human disease. Intern Med 1995;237:529-536.
66. McConkey DJ, Orrenius S. Signal transduction pathways to apoptosis. Trends Cell Biol 1994;4:370-375.
67. Dowd DR. Calcium regulation of apoptosis. In: Means AR, ed. Advances in Second Messenger and Phosphoprotein Research, Vol. 30. New York: Raven Press, 1995:255-280.
68. Alnemri ES, Litwack G. Activation of internucleosomal DNA cleavage in human CEM lymphocytes by glucocorticoid and novobiocin. Biol Chem 1990;265:17323-17333.
69. Lam M, Dubyak G, Distelhorst CW. Effect of glucocorticosteroid treatment on intracellular calcium homeostasis in mouse lymphoma cells. Mol Endocrinol 1993;7:686-693.
70. 2+ are not required to trigger apoptosis in human leukemia cells. Clin Exp Immunol 1992;87:465-471.
71. Kluck RM, McDougall CA, Harmon BV, Halliday JW. Calcium chelators induce apoptosis - evidence that raised intracellular ionised calcium is not essential for apoptosis. Biochim Biophys Acta 1994;1223:247-254.
72. Zhu WH, Loh TT. Roles of calcium in the regulation of apoptosis in HI-60 promyelocytic leukemia cells. Life Sci 1995;57:2091-2099.
73. Whyte MKB, Hardwick SJ, Meagher LC, Savill JS, Haslett C. Transient elevations of cytosolic free calcium retard subsequent apoptosis in neutrophils in vitro. Clin Invest 1993;92:446-455.
74. -1. Immunology 1992;148:1416-1422.
75. Preston GA, Barrett JC, Biermann JA, Murphy E. Effects of alterations in calcium homeostasis on apoptosis during neoplastic progression. Cancer Res 1997;57:537-542.
76. Williams GT. Programmed Cell Death: Apoptosis and Oncogenesis. Cell 1991;65:1097-1098.
77. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993; 341:1251-1254.
78. Wright SC, Zhong J, Larrick JW. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 1994;8:654-660.
79. Bursch W, Oberhammer F, Schulte-Hermann R. Cell death by apoptosis and its protective role against disease. Trends Pharmacol Sci 1992;13:245-251.
80. Bursch W, Lauer B, Timmermann-Trosiener I, Barthel G, Schuppler J, Schulte-Hermann R. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984;5:453-458.
81. Schulte-Hermann R, Timmermann-Trosier I, Barthel G, Bursch W. DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res 1990;50: 5127-5135.
82. James NJ, Roberts RA. Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. Carcinogenesis 1996;17:1623-1632.
83. Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 1990;17: 175-187.
84. S4. Connor J, Sawczuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA, Buttyan R. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988;13:119-130.
85. 2+ channels exposed to serum from patients with type I diabetes. Science 1993;261:86-90.
86. Leszczynski D, Zhao Y, Luokkamaeki M, Foegh ML. Apoptosis of vascular smooth muscle cells. Am J Pathol 1994; 145:1265-1270.
87. Shchepotin IB, Soldatenkov VA, Shabahang M, Buras RR, Nauta RJ, Evans SRT. The effect of hyperthermia and verapamil on primary and metastatic colon adenocarcinoma cell lines: Inhibition of proliferation, cell cycle distribution and onset of apoptosis. Oncol Rep 1995;2:879-884.
88. Shamash I, Davies DC, Lister TA. Apoptosis and cell proliferation control induced by pulsed calcium channel blockade in a low grade lymphoma cell line expressing BCL-2. Blood 1994;84:448A.
89. Balakumaran A, Campbell GA, Treinen Moslen M. Calcium channel blockers induce thymic apoptosis in vivo in rats. Toxicol Appl Pharmacol 1996;139:122-127.
90. Smith BM, Ginhart TD, Culburn NH. Extracellular calcium requirement for promotion of transformation in JB6 cells. Cancer Res 1986;46:701-706.
91. Tatsuta M, Iishi H, Baba M, Nakaizumi A, Uehara H, Taniguchi H. Effect of calcium channel blockers on gastric carcinogenesis and caerulein enhancement of gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res 1990;50:2095-2098.
92. Nakaizumi A, Uehara H, Baba M, Iishi H, Tatsuta M. Inhibition by verapamil of cholecystokinin-enhancement of pancreatic carcinogenesis induced by azaserine in Wistar rats. Cancer Lett 1996;105:23-27.
93. Juraskova V, Sladek T. Antimetastatic action of diltiazem on LS/BL tumor cells in liver tumor-colony assay. Neoplasma 1990;37:343-348.
94. Onoda JM, Sloane BF, Taylor JD, Honn KV. Calcium channel blockers: Inhibition of tumor cell-platelet-endothelial cell interactions. Dev Oncol 1984;22:244-258.
95. Honn KV, Onoda JM, Taylor JD, Sloane BF. Antimetastatic therapy with calcium active compounds. In: Hellmann Eccles SA, ed. Treatment and Metastasis: Problems and Prospects. London. Taylor and Francis, 1984:259-262.
96. 3 and tumor-cell-induced platelet aggregation. Cancer Rev Clin Oncol 1992;118:425-434.
97. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Clin Oncol 1991;9:17-24.
98. Gupta V, Kamath N, Tkalcevic GT, Singh SV. Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line. Biochem Pharmacol 1994;47:1701-1704.
99. Cole K, Kohn E. Calcium-mediated signal transduction: Biology, biochemistry, and therapy. Cancer Metast Rev 1994; 13:31-14.
100. Zacharski LR, Moritz TE, Haakenson CM, Odonnell JF, Ballard HS. Chronic calcium antagonist use in carcinoma of the lung and colon, a retrospective cohort observational study. Cancer Invest 1990;8:451-458.
101. Brown M. Letter to the Editor. Lancet 1996;348:1166.
102. Jick H, Jick S, Derby LE, Vaslakis C, Myers MW, Meier CR. Calcium channel blockers and risk of cancer. Lancet 1997;349:525-528.
103. Olson JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997;29:1091-1094.
104. Ad Hoc Subcommittee of the Liaison Committee of the WHO and the International Society of Hypertension. Effects of calcium antagonists on the risk of coronary heart disease, cancer and bleeding. J Hypertens 1997;15:105-115.
105. Anundi I. Calcium antagonists and cancer - what do studies of animals used in experiments show? Information from Läkemedelsverket 1997;8:1-4.